GYRE THERAPEUTICS INC (GYRE)
US4037831033 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.34M -64.96% | 790K -89.24% | 113.45M 14,260.76% | 142.18M 25.32% | 160.59M 12.95% | 208.5M 29.83% | -100.00% | ||||
| EBITDA YoY % growth | -87.59M -55.11% | -29.21M 66.65% | 20.287M 169.45% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.89M -55.37% | -29.41M 66.54% | 19.213M 165.33% | 31.752M 65.26% | 45.38M 42.92% | 69.264M 52.63% | -100.00% | ||||
| Operating Margin | -1,197.41% | -3,722.78% | 16.94% | 22.33% | 28.26% | 33.22% | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -2.87 -1.41% | N/A 590.45% | N/A -117.39% | 0.46 118.65% | 0.64 40.62% | 0.97 50.33% | N/A | N/A | N/A | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | 61.90% | -0.61 | % | |
| Q3 2023 Q2Q % growth | -1.05 56.25% | -0.77 | -0.29 | -37.25% |
| Q2 2023 Q2Q % growth | -1.05 61.11% | -1.07 | 0.02 | 1.96% |
| Q1 2023 Q2Q % growth | 0.15 102.17% | -1.07 | 1.22 | 114.01% |
| Q4 2022 Q2Q % growth | -151.02% | -1.61 | % | |
| Q3 2022 Q2Q % growth | -2.40 -200.00% | -1.53 | -0.87 | -56.86% |
| Q2 2022 Q2Q % growth | -2.70 -321.88% | -3.75 | 1.05 | 27.97% |
| Q1 2022 Q2Q % growth | -6.90 -773.42% | -6.78 | -0.12 | -1.73% |
| Q4 2021 Q2Q % growth | -0.64 25.58% | -0.60 | -0.04 | -6.80% |
| Q3 2021 Q2Q % growth | -0.80 -9.59% | -0.67 | -0.13 | -18.84% |
| Q2 2021 Q2Q % growth | -0.64 33.33% | -0.71 | 0.07 | 9.72% |
| Q1 2021 Q2Q % growth | -0.79 -182.14% | -0.59 | -0.20 | -34.11% |
| Q4 2020 Q2Q % growth | -0.86 23.89% | -0.88 | 0.02 | 2.24% |
| Q3 2020 Q2Q % growth | -0.73 31.13% | -0.82 | 0.09 | 11.28% |
| Q2 2020 Q2Q % growth | -0.96 16.52% | -0.88 | -0.08 | -9.12% |
| Q1 2020 Q2Q % growth | -0.28 77.78% | -0.37 | 0.09 | 24.79% |
| Q4 2019 Q2Q % growth | -1.13 | -0.32 | -0.81 | -251.70% |
| Q3 2019 Q2Q % growth | -1.06 | -1.09 | 0.03 | 2.88% |
| Q2 2019 Q2Q % growth | -1.15 | -1.14 | -0.01 | -1.27% |
| Q1 2019 Q2Q % growth | -1.26 | -1.10 | -0.16 | -14.91% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | -100.00% | % | ||
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2022 Q2Q % growth | 790K -46.26% | 790K | % | |
| Q4 2021 Q2Q % growth | 2.44M 20.20% | 170.003K | 2.27M | 1,335.27% |
| Q3 2021 Q2Q % growth | 2.3M 158.43% | 688.5K | 1.612M | 234.06% |
| Q2 2021 Q2Q % growth | 1.13M -31.93% | 339.997K | 790.003K | 232.36% |
| Q1 2021 Q2Q % growth | 1.47M -91.02% | 816K | 654K | 80.15% |
| Q4 2020 Q2Q % growth | 2.03M | 51K | 1.979M | 3,880.39% |
| Q3 2020 Q2Q % growth | 890K | 1.071M | -181K | -16.90% |
| Q2 2020 Q2Q % growth | 1.66M | 306K | 1.354M | 442.48% |
| Q1 2020 Q2Q % growth | 16.37M | 8.109M | 8.261M | 101.87% |
| Q4 2019 Q2Q % growth | 7.65M | -7.65M | -100.00% | |
| Q3 2019 Q2Q % growth | 306K | -306K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 0% |
| Revenue | N/A | N/A | 0% | 0% |